CN111201246B - 结合补体成分c5或血清白蛋白的多肽及其融合蛋白 - Google Patents

结合补体成分c5或血清白蛋白的多肽及其融合蛋白 Download PDF

Info

Publication number
CN111201246B
CN111201246B CN201880046102.3A CN201880046102A CN111201246B CN 111201246 B CN111201246 B CN 111201246B CN 201880046102 A CN201880046102 A CN 201880046102A CN 111201246 B CN111201246 B CN 111201246B
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
engineered polypeptide
specifically binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880046102.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN111201246A (zh
Inventor
布里奇特·帞菲
朱利安·钱德
尼米斯·基拉
道格拉斯·L·谢里登
赛达斯·金达尔
保罗·P·腾博尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Priority to CN202311281139.3A priority Critical patent/CN117327188A/zh
Priority to CN202311281093.5A priority patent/CN117327187A/zh
Publication of CN111201246A publication Critical patent/CN111201246A/zh
Application granted granted Critical
Publication of CN111201246B publication Critical patent/CN111201246B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN201880046102.3A 2017-07-11 2018-07-11 结合补体成分c5或血清白蛋白的多肽及其融合蛋白 Active CN111201246B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202311281139.3A CN117327188A (zh) 2017-07-11 2018-07-11 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
CN202311281093.5A CN117327187A (zh) 2017-07-11 2018-07-11 结合补体成分c5或血清白蛋白的多肽及其融合蛋白

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762531215P 2017-07-11 2017-07-11
US62/531,215 2017-07-11
PCT/US2018/041661 WO2019014360A1 (en) 2017-07-11 2018-07-11 POLYPEPTIDES BINDING COMPONENT C5 OR SERUM ALBUMIN COMPONENT AND FUSION PROTEINS THEREOF

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202311281139.3A Division CN117327188A (zh) 2017-07-11 2018-07-11 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
CN202311281093.5A Division CN117327187A (zh) 2017-07-11 2018-07-11 结合补体成分c5或血清白蛋白的多肽及其融合蛋白

Publications (2)

Publication Number Publication Date
CN111201246A CN111201246A (zh) 2020-05-26
CN111201246B true CN111201246B (zh) 2023-10-27

Family

ID=63036501

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202311281139.3A Pending CN117327188A (zh) 2017-07-11 2018-07-11 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
CN201880046102.3A Active CN111201246B (zh) 2017-07-11 2018-07-11 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
CN202311281093.5A Pending CN117327187A (zh) 2017-07-11 2018-07-11 结合补体成分c5或血清白蛋白的多肽及其融合蛋白

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202311281139.3A Pending CN117327188A (zh) 2017-07-11 2018-07-11 结合补体成分c5或血清白蛋白的多肽及其融合蛋白

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311281093.5A Pending CN117327187A (zh) 2017-07-11 2018-07-11 结合补体成分c5或血清白蛋白的多肽及其融合蛋白

Country Status (12)

Country Link
US (3) US11498960B2 (enExample)
EP (1) EP3625265A1 (enExample)
JP (3) JP7684803B2 (enExample)
KR (3) KR102806328B1 (enExample)
CN (3) CN117327188A (enExample)
AU (3) AU2018301412B2 (enExample)
BR (1) BR112019028269A2 (enExample)
CA (1) CA3067247A1 (enExample)
CO (1) CO2020000369A2 (enExample)
IL (3) IL271920B2 (enExample)
MX (2) MX2024005945A (enExample)
WO (1) WO2019014360A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117327188A (zh) 2017-07-11 2024-01-02 亚力兄制药公司 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
WO2020092546A1 (en) * 2018-10-30 2020-05-07 Alexion Pharmaceuticals, Inc. Co-administration of a hyaluronidase and anti-c5 antibody for treatment of complement-associated conditions
WO2020214679A1 (en) * 2019-04-16 2020-10-22 University Of Washington Amantadine binding protein
TWI844709B (zh) 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
CN114867484B (zh) 2019-12-26 2024-08-06 卫材R&D管理有限公司 含有抑制补体c5的表达的双链核糖核酸的药物组合物
WO2021144962A1 (ja) 2020-01-17 2021-07-22 オリンパス株式会社 発光装置、および駆動装置
WO2021211940A1 (en) 2020-04-16 2021-10-21 Assistance Publique, Hopitaux De Paris Methods for treating a complement mediated disorder caused by viruses
US20230357442A1 (en) * 2020-10-05 2023-11-09 Alexion Pharmaceuticals, Inc. Methods of treating dermatomyositis
TW202417490A (zh) * 2022-08-31 2024-05-01 美商艾力克森製藥公司 用於治療鐮狀細胞病的融合多肽之劑量及投與
CN116731149B (zh) * 2023-06-07 2024-02-27 华中农业大学 草鱼补体活化分子碳末端肽C5a-CP及应用
CN119241699B (zh) * 2024-09-24 2025-11-28 广州康盛生物科技股份有限公司 一种抗人补体c5的单域抗体及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010151526A1 (en) * 2009-06-23 2010-12-29 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins
WO2011095545A1 (en) * 2010-02-05 2011-08-11 Ablynx Nv Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
AU2012254935A1 (en) * 2004-02-12 2012-12-06 Archemix Llc Aptamer Therapeutics Useful in the Treatment of Complement-Related Disorders
CN103003301A (zh) * 2010-05-03 2013-03-27 百时美施贵宝公司 血清白蛋白结合分子

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
DE69330523D1 (de) 1992-08-21 2001-09-06 Vrije Universiteit Brussel Bru Immunoglobuline ohne leichte ketten
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
ES2294799T3 (es) 1996-06-27 2008-04-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Moleculas de anticuerpos que interactuan especificamente con el sitio activo o hendidura de una molecula diana.
BR9813276A (pt) 1997-10-27 2000-08-22 Unilever Nv Proteìna multivalente de ligação de antìgeno, sequências de nucleotìdeos, vetor de expressão, célula hospedeira, processo para preparação de proteìna multivalente de ligação de antìgeno, e, uso da mesma
JP2003518075A (ja) 1999-12-24 2003-06-03 ジェネンテック・インコーポレーテッド 生理活性化合物の消失半減期延長のための方法及び組成物
DK1355919T3 (da) * 2000-12-12 2011-03-14 Medimmune Llc Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
KR100708398B1 (ko) 2002-03-22 2007-04-18 (주) 에이프로젠 인간화 항체 및 이의 제조방법
AU2003286002B2 (en) * 2002-11-08 2011-06-16 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
JP2006519763A (ja) 2002-11-08 2006-08-31 アブリンクス エン．ヴェー． 治療用ポリペプチドの投与法およびそのためのポリペプチド
EP2390270A1 (en) 2003-01-10 2011-11-30 Ablynx N.V. Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation
AU2005250216B2 (en) * 2004-06-01 2009-12-10 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
CN100368022C (zh) 2005-09-20 2008-02-13 中国人民解放军第二军医大学 双重靶向抗肝纤维化药物载体拟糖蛋白纳米粒及其制法
BRPI0617688A2 (pt) * 2005-10-21 2011-06-07 Hoffmann La Roche método para expressão recombinante de um polipeptìdeo
SI2500030T2 (sl) 2005-11-04 2018-11-30 Genentech, Inc. Uporaba inhibitorjev komplementarnih procesov za zdravljenje očesnih bolezni
ES2538114T3 (es) 2008-03-03 2015-06-17 Novelmed Therapeutics, Inc. Anticuerpos anti-properdina
MX2011001371A (es) 2008-08-05 2011-06-16 Novartis Ag Composiciones y metodos para anticuerpos que se dirigen a la proteina de complementos c5.
CN102482701B (zh) 2009-09-16 2015-05-13 免疫医疗公司 I类抗-cea抗体及其使用
US9644022B2 (en) 2009-11-30 2017-05-09 Ablynx N.V. Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
CA2811221C (en) 2010-03-10 2018-01-09 Novelmed Therapeutics, Inc. Humanized and chimeric anti-properdin antibodies
WO2012004384A2 (en) 2010-07-09 2012-01-12 Affibody Ab Polypeptides
TW201241008A (en) 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
US9701742B2 (en) 2011-07-01 2017-07-11 The Trustees Of The University Of Pennsylvania Anti-properdin antibodies and uses thereof
PE20150159A1 (es) 2011-12-21 2015-02-08 Novartis Ag Composiciones y metodos para anticuerpos que actuan sobre el factor p
AU2012362217A1 (en) 2011-12-28 2014-07-24 Novelmed Therapeutics, Inc. Aglycosylated human antibody and fusion protein and uses thereof
RS58503B1 (sr) 2012-02-20 2019-04-30 Swedish Orphan Biovitrum Ab Publ Polipeptidi koji se vezuju za humani komplement c5
JP2015532303A (ja) 2012-10-04 2015-11-09 ノベルメド セラピューティクス，インコーポレーテッド 溶血性疾患を治療するための補体第２経路特異的抗体
MX367423B (es) 2013-08-28 2019-08-21 Affibody Ab Polipeptidos de union a c5.
LT3038633T (lt) 2013-08-28 2021-03-25 Ipc Research, Llc Stabilūs polipeptidai, kurie rišasi prie žmogaus komplemento c5
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
MX2019008827A (es) 2017-01-30 2019-09-26 Alexion Pharma Inc Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo.
CN117327188A (zh) 2017-07-11 2024-01-02 亚力兄制药公司 结合补体成分c5或血清白蛋白的多肽及其融合蛋白

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012254935A1 (en) * 2004-02-12 2012-12-06 Archemix Llc Aptamer Therapeutics Useful in the Treatment of Complement-Related Disorders
WO2010151526A1 (en) * 2009-06-23 2010-12-29 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins
WO2011095545A1 (en) * 2010-02-05 2011-08-11 Ablynx Nv Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
CN103003301A (zh) * 2010-05-03 2013-03-27 百时美施贵宝公司 血清白蛋白结合分子

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria;Rother R P ET AL;《Nature Biotechnology》;第25卷(第11期);1256-1264 *
General Strategy to Humanize a Camelid Single-domain Antibody and Identification of a Universal Humanized Nanobody Scaffold;Cécile Vincke等;《JBC》;第284卷(第284期);3273-3284 *
Generation and production of engineered antibodies;Kipriyanov Sergey M et al;《Molecular Biotechnology》;第26卷(第1期);39-60 *
Selection and identification of single domain antibody fragments from camel heavy-chain antibodies;M Arbabi Ghahroudi el al;《FEBS Letters》;第414卷(第3期);521-526 *
The clinical potential of affibody-based inhibitors of C5 for therapeutic complement disruption;Berglund Margnus M et al;《Expert review of proteomics》;第13卷(第3期);241-243 *
The preclinical pharmacology of the high affinity anti-IL6R nanobody? Alx-0061 supports its arthritis;Maarten Van Roy et al;《Arthritis Research and Therapy》;第17卷(第1期);2 *
人补体片段C5a蛋白的可溶性表达、纯化及生物学活性检测;吕永强;《中国医药导刊》;第10卷(第10期);1-5 *

Also Published As

Publication number Publication date
JP2020532285A (ja) 2020-11-12
JP7684803B2 (ja) 2025-05-28
IL271920A (en) 2020-02-27
IL271920B2 (en) 2024-03-01
US20250163138A1 (en) 2025-05-22
MX2024005946A (es) 2024-06-11
CN117327188A (zh) 2024-01-02
WO2019014360A1 (en) 2019-01-17
KR20250068795A (ko) 2025-05-16
KR102806328B1 (ko) 2025-05-14
BR112019028269A2 (pt) 2020-07-14
RU2020102910A3 (enExample) 2021-12-02
US11498960B2 (en) 2022-11-15
CA3067247A1 (en) 2019-01-17
KR20200026264A (ko) 2020-03-10
AU2018301412A9 (en) 2025-08-07
IL307197B1 (en) 2025-11-01
AU2018301412B2 (en) 2025-08-07
AU2025200313A1 (en) 2025-02-13
WO2019014360A8 (en) 2019-02-21
MX2024005945A (es) 2024-06-11
JP2025118590A (ja) 2025-08-13
US12221473B2 (en) 2025-02-11
RU2020102910A (ru) 2021-08-11
IL324119A (en) 2025-12-01
US20230235033A1 (en) 2023-07-27
KR20250099285A (ko) 2025-07-01
CN111201246A (zh) 2020-05-26
IL307197A (en) 2023-11-01
CN117327187A (zh) 2024-01-02
AU2025200303A1 (en) 2025-02-13
US20200399351A1 (en) 2020-12-24
JP2023120208A (ja) 2023-08-29
EP3625265A1 (en) 2020-03-25
IL271920B1 (en) 2023-11-01
AU2018301412A1 (en) 2020-01-30
CO2020000369A2 (es) 2020-01-31

Similar Documents

Publication Publication Date Title
CN111201246B (zh) 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
KR102453227B1 (ko) 항-axl 길항성 항체
CN111744007B (zh) 一种抗tigit抗体药物组合物及其用途
CN117440973A (zh) 与ror1结合的抗原结合蛋白
WO2021155635A1 (zh) 抗cd3和cd123双特异性抗体及其用途
US20240239878A1 (en) Binding molecule against dll3 and use thereof
TWI801425B (zh) Il-5 抗體、其抗原結合片段及醫藥用途
CN116284377A (zh) 抗人血管生成素3纳米抗体及其应用
JP2014526886A (ja) マクロファージ遊走阻止因子（ｍｉｆ）とｄ−ドーパクロームトートメラーゼ（ｄ−ｄｔ）に交差反応性がある抗体
TW202409074A (zh) 鬆弛素或類似物的融合蛋白及其醫藥用途
CN117279947A (zh) 用于在增殖性疾病中使用的靶向cd20和cd22的抗原结合分子
US20250019457A1 (en) Trop2 antibodies
WO2024104431A1 (zh) 一种靶向FRα的抗体或其抗原结合片段及其应用
RU2794359C2 (ru) Полипептиды, которые связываются с компонентом комплемента c5 или сывороточным альбумином, и их белки слияния
HK40027205A (en) Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof
HK40027205B (zh) 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
JP7564882B2 (ja) Ａｒｅｇに対する抗体及びその用途
WO2025171256A1 (en) Compositions and methods for treating malaria
JP2024535249A (ja) 合成ヒト化ラマナノボディライブラリーおよびｓａｒｓ－ｃｏｖ－２中和抗体を同定するためのその使用
WO2025101747A1 (en) Methods and compositions for treatment of pulmonary hypertension

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40027205

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CP02 Change in the address of a patent holder

Address after: Massachusetts

Patentee after: Alexion pharmaceutical Co.

Address before: Connecticut, USA

Patentee before: Alexion pharmaceutical Co.

CP02 Change in the address of a patent holder